EXPECTED ACCOMPLISHMENTS AND GOALS. [Describe what products the Participant might be manufacturing or commercializing as a result of the efforts under this CRADA. { If no products can be identified, then state so.}]
EXPECTED ACCOMPLISHMENTS AND GOALS. The proposed project is aimed at developing a disruptive prototyping paradigm for [INSERT description, e.g, biomanufacturing, allowing rapid discovery of novel biological pathways to advanced materials and chemicals through cell-free systems]. If successful, this project could drastically alter materials discovery and development with the potential for sweeping impacts on manufacturing capabilities, energy efficiency, and enabling materials and chemicals-based technologies.
EXPECTED ACCOMPLISHMENTS AND GOALS. The project will use 25 kg of 99.9% enriched 28Si, 500 g of 90% enriched 29Si, and 500 g of 90% enriched 30Si to be provided by Krasnoyarsk-45 as their commitment. (All weights refer to the amount of Si regardless of the chemical form, i.e., silane, trichlorosilane, etc.) The project goals are the following: o Manufacture 28Si epitaxial layers on natural Si wafer up to 8" (200 mm) in size for fabrication of IC test circuits and for thermal conductivity testing with the goal of establishing isotopically enriched Si as a viable component of the semiconductor manufacturing process. o Produce 0.25-1.0" diameter 28Si boules using poly-28Si as a starting material. o Generate high-quality P-doped (n-type) Si material via neutron transmutation doping (NTD) of highly 30Si -enriched material.
EXPECTED ACCOMPLISHMENTS AND GOALS. The overall goal of this project is to develop small molecule inhibitors of bacterial Gyrase B (GyrB) and Par E (ParE) that can be used as new Gram-negative broad-spectrum antibacterial agents that have no cross-resistance to existing drugs. The project will take promising structural analogs and advance them through lead optimization to a clinical product with demonstrated in vivo efficacy. The proposed cooperative project addresses a critical gap in our ability to treat certain diseases in the civilian population. Development of countermeasures for these diseases is a mission of the sponsor, the National Institute of Allergy and Infectious Diseases (NIAID) which is an institute of the National Institutes of Health within the U.S. Department of Health and Human Services. Specifically, there is a need for new therapeutics that are effective against biological agents that could be used in terrorist attacks against the civilian population. The NIAID has a mission to advance the development of such new medical countermeasures. At the present time treatment options for many of the NIAID priority biodefense pathogens are either non-existent or limited and vulnerable to emerging antimicrobial resistance and genetically engineered threats. Within this framework, the development of new antimicrobial agents with broad spectrum activity is a high priority. 08IS1120 SOW App. A 2/10 TC02128.0 Trius Therapeutics, Inc.
